首页> 外文期刊>Biochemical Pharmacology >Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on celecoxib-induced apoptosis.
【24h】

Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on celecoxib-induced apoptosis.

机译:抗凋亡Bcl-2家族成员Mcl-1,Bcl-2和Bcl-xL对塞来昔布诱导的细胞凋亡的差异作用。

获取原文
获取原文并翻译 | 示例
           

摘要

The cyclooxygenase-2 inhibitor Celecoxib is a potent inducer of apoptosis in tumor cells. In most cellular systems Celecoxib induces apoptosis via an intrinsic, mitochondrial apoptosis pathway. We recently showed that in Bax-negative Jurkat cells expression of pro-apoptotic Bak is essential for Celecoxib-induced mitochondrial damage and apoptosis induction. Aim of the present study was to identify specific pro- and anti-apoptotic members of the Bcl-2 family involved in the regulation of Bak activation, and subsequent apoptosis upon treatment with Celecoxib in the Jurkat cell model. Our results show that apoptosis in response to Celecoxib required the presence of Noxa and downregulation of the anti-apoptotic protein Mcl-1. Celecoxib-induced Bak activation and subsequent apoptosis could be inhibited by overexpression of Bcl-xL but not by the very similar Bcl-2. In Bcl-xL-overexpressing cells neutralization of both, Mcl-1 and Bcl-xL, was prerequisite for an efficient induction of apoptosis. Our data reveal an important role of the Mcl-1/Noxa axis for Celecoxib-induced apoptosis and suggest that Celecoxib may be of value for treatment of tumors addicted to Mcl-1 and for combined treatment approaches targeting anti-apoptotic Bcl-2 family members.
机译:环氧合酶2抑制剂塞来昔布是肿瘤细胞凋亡的有效诱导剂。在大多数细胞系统中,塞来昔布通过固有的线粒体凋亡途径诱导凋亡。我们最近显示,在Bax阴性Jurkat细胞中,促凋亡Bak的表达对于Celecoxib诱导的线粒体损伤和细胞凋亡诱导至关重要。本研究的目的是确定在Jurkat细胞模型中,Bcl-2家族的特定促凋亡和抗凋亡成员参与Bak激活的调控,以及随后用塞来昔布治疗后的凋亡。我们的结果表明,响应Celecoxib的凋亡需要存在Noxa和下调抗凋亡蛋白Mcl-1。塞来昔布诱导的Bak激活和随后的细胞凋亡可以通过Bcl-xL的过表达来抑制,但不能通过非常相似的Bcl-2来抑制。在Bcl-xL过表达的细胞中,Mcl-1和Bcl-xL的中和是有效诱导细胞凋亡的前提。我们的数据揭示了Mcl-1 / Noxa轴对于Celecoxib诱导的细胞凋亡的重要作用,并表明Celecoxib对于治疗Mcl-1上瘾的肿瘤以及针对抗凋亡Bcl-2家族成员的联合治疗方法可能具有价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号